Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company whose news flow centers on vascular interventions, oncology technologies, and corporate developments. Company announcements emphasize its focus on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients.
News releases frequently highlight performance across AngioDynamics’ two main platforms, Med Tech and Med Device. Investors can follow updates on Med Tech growth, including results from the Auryon peripheral atherectomy platform, the Mechanical Thrombectomy business (AngioVac and AlphaVac), and the NanoKnife irreversible electroporation platform. Earnings reports describe trends in Med Tech and Med Device net sales, gross margin, and the use of non‑GAAP measures such as adjusted EBITDA and pro forma results.
AngioDynamics also issues news about regulatory milestones and clinical studies. Recent items include FDA IDE approvals for the APEX‑Return study evaluating the AlphaReturn Blood Management System with AlphaVac F1885 in acute pulmonary embolism, and the PAVE clinical study assessing the AngioVac System for right‑sided infective endocarditis. The company has reported FDA 510(k) clearance for a modified AlphaVac F1885 System with expanded indications, as well as publication of the PRESERVE study of the NanoKnife System for prostate tissue ablation in European Urology.
Additional news topics include recognition of the NanoKnife System on TIME’s 2025 Best Inventions list, enrollment milestones in trials such as AMBITION BTK and RECOVER‑AV, participation in investor conferences, and scheduling of quarterly earnings calls. For investors and observers, the ANGO news stream offers insight into product performance, clinical evidence, regulatory progress, and the company’s strategic focus on Med Tech growth.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the UBS Global Healthcare Conference on May 23, 2022, at 4:15 p.m. ET. The presentation will focus on the company's innovations in medical technology aimed at restoring blood flow, enhancing cancer treatments, and improving patient quality of life. A live webcast will be available on the company’s website, with replay options following the event. AngioDynamics is recognized for addressing critical healthcare needs with its advanced technologies.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in medical technology, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the BofA Securities Healthcare Conference on May 10, 2022, at 10:00 a.m. PT (1:00 p.m. ET). The presentation can be viewed via live webcast on the company’s website and will be available for replay afterward. AngioDynamics specializes in restoring blood flow, expanding cancer treatment options, and enhancing patient quality of life through innovative healthcare solutions.
AngioDynamics reported a net sales increase of 3.9% to $74.0 million in Q3 fiscal 2022. Med Tech sales soared 28.6%, but Med Device saw a 2.8% decline. The gross margin decreased by 190 basis points to 52.2%. The company posted a GAAP loss per share of $0.13, though adjusted EPS rose to $0.03. Key FDA approvals were achieved for AlphaVac F18, and the company initiated the PRESERVE study. Despite challenges from COVID and inflation, AngioDynamics remains optimistic about long-term growth, projecting FY2022 net sales between $310 and $315 million.
AngioDynamics, a medical technology leader, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 2:15 p.m. ET. Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will represent the company. A live webcast of the presentation will be available on AngioDynamics' website, with a replay accessible post-event. The company specializes in technologies aimed at restoring healthy blood flow and improving patient quality of life, catering to unmet medical needs.
AngioDynamics, Inc. (NASDAQ: ANGO) will announce its third-quarter fiscal year 2022 financial results on April 7, 2022, before market opening. A conference call hosted by management will commence at 8:00 a.m. ET on the same day, allowing investors to discuss the financial outcomes. Participants can join the call via phone or access the live webcast from the AngioDynamics website. The call's recording will be available for playback shortly after its conclusion. AngioDynamics specializes in innovative, minimally invasive medical devices for various healthcare applications.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that President and CEO Jim Clemmer and CFO Stephen Trowbridge will present at three investor conferences in March 2022. The conferences include:
- Oppenheimer Virtual Healthcare Conference: March 15, 2022, at 8:40 a.m. ET
- Barclays Global Healthcare Conference: March 16, 2022, in Miami Beach, FL, at 9:00 a.m. ET
- KeyBanc Virtual Life Sciences & MedTech Investor Forum: March 22, 2022, at 3:45 p.m. ET
Live webcasts will be available on the company's website.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 10:00 a.m. ET. This event is designed for BTIG clients. AngioDynamics specializes in devices for vascular access, peripheral vascular disease, and oncology, featuring a diverse product line including ablation systems and vascular access products. For more details, visit www.angiodynamics.com.
AngioDynamics reported fiscal Q2 2022 net sales of $78.3 million, up 7.6% year-over-year. Med Tech sales surged 36.4%, while Med Device grew 0.8%. Gross margin declined to 51.8%, impacted by a $4 million backlog due to ongoing supply chain challenges. The company recorded a GAAP loss per share of $0.21 and an adjusted loss of $0.02. Full market release of the AlphaVac device occurred post-quarter. Fiscal year 2022 revenue guidance remains at $310-315 million, but gross margin guidance was revised down to 52.0%-54.0%.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 24th Annual Needham Virtual Growth Conference on January 10, 2022, at 2:00 p.m. ET. Investors can access a live webcast through the Company’s website, with a replay available afterward. AngioDynamics specializes in products for vascular access, peripheral vascular disease, and oncology, including market-leading ablation systems and vascular access products.
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its second quarter financial results for fiscal year 2022 on January 6, 2022, prior to market open. The management will conduct a conference call at 8:00 a.m. ET on the same day to discuss these results. Interested participants can join by calling 1-877-407-0784 domestically or +1-201-689-8560 internationally, using passcode 13725681. The call will also be accessible via webcast on AngioDynamics' website, with a replay available later that day.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
